<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle24
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle25
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle26
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle27
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle28
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle29
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle30
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle31
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:92097278;
mso-list-template-ids:1847760744;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1923833191;
mso-list-template-ids:-78590828;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Dissemination and Implementation Research in Health (R03 / R21 R01 Clinical Trial Optional)</span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D276.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=ExqrEwt2n9fIkLxyxL8aFZ8-Wthghlh7wSxesReCK80&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R03</span></a><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D275.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=RnrAz00b_TEeKXpY-YTgGcZ9IhmUPMlfK-KdChrBBFQ&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R21</span></a><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D274.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=axSkfVdqS3fNkVUgxYejvCc2OtYbPy81te2nSQlQ6Ak&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R01</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the
adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of
interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2022.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D277.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=8uvLgQWv8k3U_XEnjhg2mpiJYAjpfiSNlkzg-3rPejQ&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is
to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating
methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D278.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=Y7CLtn1NkZeQ4HF37nPDIVVDMTMcQjhRJEWFRESQ4FA&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance
Use Disorders (R21/R33 Clinical Trial Not Allowed)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant
phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development
of future prevention, diagnostic, and therapeutic strategies<b>.<br>
<span style="color:red"> </span></b></span><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D287.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=XSs99jCMQ9A05zGiJNtkiNb1_yHyLfpscu9Vwk_F5UI&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The National Cancer Institute’s (NCI)
</span><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.csbconsortium.org_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=O-eOt7VBBJ4GkbfwcVk5WBNno8uNOMUaRb92RKuUW1M&e=" title="Link to Non-U.S. Government Site"><span style="font-size:12.0pt;font-family:Palatino;color:black">Cancer Systems Biology Consortium</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black">
(CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected
to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this
Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D282.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=aDr7gnqyyfIq20VhwIYw4hdAv7rFijr-u5mIe2QNDCc&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental
in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAG-2D20-2D025.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=p9633tbtDwEUom-32ghSW07XWhhzFR2CaLVceuO3Kzs&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R01</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer’s disease (AD).
This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about
senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R 21 / R01 Clinical Trial Optional)</span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D280.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=IC1_Q-fQqLv5j395fg2JAMtMc3KzjVBia9CiiKC20SA&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R21</span></a><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D279.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=9jP8ruLv1cTvggkBsZiAgjyp3QeGi7gwTih6jpZzQs4&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R01</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Through these Funding Opportunity Announcements (FOAs), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes
in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in multiple
myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. These FOAs
include six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application)
proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from
multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D281.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=8yh71tsHccqE2Mamy2hjbwKAXwuiczUF57fAlLAj6cg&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated
clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about
the research mission and high-priority research areas of the NIAID (<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.niaid.nih.gov_research_role&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=HISU9c_4T-Qt_gI0tcvWW97UImqSTnv9vpig387I6e8&e=">https://www.niaid.nih.gov/research/role</a>).</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDA-2D20-2D001.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=ouOHnf6dnpARQrP4JRmsu4DjzfbOqyYRSy-Pcd5-CgU&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial
Not Allowed)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational
activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities
with a primary focus on <i>Courses for Skills Development</i>. In particular, NIDA/NIMH are interested in supporting short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.
The purpose of this FOA is to invite applications that involve research education on the use of ABCD data through meetings/workshops involving 1. Advanced seminars relevant to analysis of ABCD data, and 2. Hands on collaborative- or competition-style use of
the ABCD dataset. Applications emphasizing the development of predictive models for identifying group/individual differences, with the overarching goal of predicting behavioral and clinical outcomes in future timepoints, are particularly encouraged. Applications
proposing prediction of outcomes within the baseline assessment (e.g., predictiing impulsivity scores at the baseline timepoint from neuroimaging measures) are encouraged to explicitly address validation strategies. The overall goals of this initiative are:</span><o:p></o:p></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Widening use of the ABCD dataset</span><o:p></o:p></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Enhancing rigor and reproducibility towards better predictive models</span><o:p></o:p></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Facilitating collaboration between clinical and computational researchers on normative and psychopathological neurodevelopment.</span><o:p></o:p></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDA-2D20-2D013.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=MwkMSAXUZL5wEs4MnrwzaZn1Nzm4iJtNIQctRBNxZI0&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US
Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding
the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact
of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health
risk behaviors with consequences such as increased occurrence of STIs.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Lucidity in Dementia (R21/R33 and R21 Clinical Trial Optional)</span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAG-2D20-2D017.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=N_1vBCJrYExHbTcHXt-durLU9rqZSH9XbvsqxRiXznY&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R21/R33</span></a><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAG-2D20-2D016.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=oljwMzXUCr9lUgP3xKncPTAhkmQypEF2tOafkbzx_ag&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R21</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Fluctuations in mental status occur commonly in dementia. Such fluctuations vary by dementia type and are most apparent in earlier stages of disease. However, even in late-stage dementia,
patients have been reported to exhibit unexpected episodes of mental clarity or lucidity, characterized by spontaneous meaningful and relevant communication at a time when the capacity for coherent speech has presumably been lost. These FOAs are intended to
advance scientific understanding of lucidity in dementia by supporting an initial set of retrospective and/or prospective studies that will lay the groundwork for further research on this topic. Results from studies supported by these FOAs have the potential
to broaden our conceptual understanding of Alzheimer’s disease and related dementias. Current models of progression and functional decline do not adequately account for spontaneous reversals of cognitive ability – even transiently – in late-stage disease.
Further study of lucid episodes in dementia could potentially expand existing paradigms and inform novel approaches for future studies. Greater understanding of lucidity in dementia may also influence families’ and caregivers’ attitudes and behaviors toward
patients with dementia, advance understanding of personhood throughout the course of dementia, and address ethical challenges or decisional conflicts among family members or other proxies who witness lucid episodes.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"> </span></b><o:p></o:p></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D269.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=UpsDizJUWEo2BA78LRSwl5DGNUNxhKZzutSePZ8Ho7E&s=VOvRv79yhpSb01E37mqWPQr_IY8eP5Yu9GYWdAPEYgo&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial
Not Allowed)</span></a><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred
to here as “cognitive systems,” that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer’s disease (AD) and Alzheimer’s disease related dementias (ADRD) via analysis
of a variety of genetic, genomic, and biomarker data that are currently available to the research community.</span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2022.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><b><span style="font-size:12.0pt;font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b><span style="font-size:12.0pt;font-family:Palatino;color:black">.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><o:p></o:p></p>
</div>
</body>
</html>